A Phase 3 Multicenter, Open-Label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Followin

Back to Results

RASOLUTE 304

A Phase 3 Multicenter, Open-Label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)